Medimmune Limited

Darren Schofield

Claire Louise Dobson

David C Lowe

Matthew Alexander Sleeman

Jonathan P Hatcher

Lorraine Irving

Iain Patrick Chessell

Changshou Gao

Scott A Hammond

Ronald Herbst

Godfrey Rainey

Stacey Drabic

Srinath Kasturirangan

Michelle Morrow

Yariv Mazor

Brian Lobo

Michael Oberst

Prakash Manikwar

Jonathan Seaman

Simon Dovedi

Gianluca Carlesso

George Thom

Kristen Pollizzi

Michael Perkinton

Peter Cariuk

Albert George Thom

David Llewellyn Rees

Elaine M Hurt

Catherine Huntington

Matthew Robinson

Fiona Cusdin

Margareta Ek

Carina Johansson

Jenny Sandmark

Josquin Nys

Aidan Riley

David Lowe

Jonathan Hatcher

The invention relates to binding molecules, such as antibodies, that bind to the chemokine receptor CCR9. More particularly, the invention relates to the treatment of CCR9-mediated diseases or conditions such as inflammatory bowel disease (IBD), and methods for the detection of CCR9, which make use of the binding molecules of the invention.

Therapeutic binding molecules

The disclosure generally provides proteins that bind two epitopes (e.g., a first and a second epitope) and that are bivalent for binding to each of the first and second epitopes. The disclosure also provides for specific binding proteins, including antibodies, which bind to a target protein. The disclosure also provides compositions comprising such proteins, nucleic acid molecules encoding such proteins and methods of making such proteins. The disclosure provides methods of inducing an immune response in a subject as well as methods for treating or preventing cancer in a subject by administering the proteins, nucleic acid molecules and/or compositions to the subject.

Bispecific binding proteins and uses thereof

This disclosure provides compositions and methods for controlling pain. In particular the disclosure provides a method for controlling pain comprising co-administration of an NGF antagonist and a TNFα antagonist. The NGF antagonist and the TNFα antagonist can be separate molecules or part of a multifunctional polypeptide, e.g., a multispecific binding molecule that comprises an NGF antagonist domain and a TNFα antagonist domain. This disclosure also provides multifunctional polypeptides, e.g., multispecific binding molecules, comprising an NGF antagonist domain, and a TNFα antagonist domain. The method provides improved pain control. Administration of an NGF antagonist and a TNFα antagonist as provided herein can control pain in the subject more effectively than an equivalent amount of the NGF antagonist or the TNFα antagonist administered alone.

Compounds and methods for treating pain

The present disclosure is directed to human GDF-15-binding antibodies and antigen-binding fragments thereof. The antibodies and fragments can be used, for example, to detect human GDF-15 and/or in methods of treating cancer or body weight loss, including cachexia, associated with over-expression of human GDF-15.

Antibodies directed against GDF-15

The invention provides antibodies that specifically bind human &#x3b1;-synuclein with a high affinity and reduces &#x3b1;-synuclein spreading in vivo, recombinant polypeptides comprising said antibodies or antigen-binding fragment thereof and methods for generating such polypeptides, as well as compositions and methods for generating &#x3b1;-synuclein antibodies, and methods of using &#x3b1;-synuclein antibodies for the treatment of diseases of the central nervous system, in particular alpha-synucleinopathies.

Antibodies to alpha-synuclein and uses thereof

This disclosure provides compositions and methods for controlling pain. In particular the disclosure provides a method for controlling pain comprising co-administration of an NGF antagonist and a TNF&#x3b1; antagonist. The NGF antagonist and the TNF&#x3b1; antagonist can be separate molecules or part of a multifunctional polypeptide, e.g., a multispecific binding molecule that comprises an NGF antagonist domain and a TNF&#x3b1; antagonist domain. This disclosure also provides multifunctional polypeptides, e.g., multispecific binding molecules, comprising an NGF antagonist domain, and a TNF&#x3b1; antagonist domain. The method provides improved pain control. Administration of an NGF antagonist and a TNF&#x3b1; antagonist as provided herein can control pain in the subject more effectively than an equivalent amount of the NGF antagonist or the TNF&#x3b1; antagonist administered alone.

Antibodies to &#x3b1;-synuclein and uses thereof

Growing community of inventors

Cambridge, United Kingdom

Darren Schofield